BioAge Labs, Inc. — Director's Dealing 2026

Jan 15, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioAge Labs, Inc. (BIOA)
CIK: 0001709941
Period of Report: 2026-01-13

Reporting Person: GOLDSTEIN DOV A MD (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-13	Common Stock	M	27000	$8.39	Acquired	49408	Direct
2026-01-13	Common Stock	S	8974	$18.4278	Disposed	40434	Direct
2026-01-13	Common Stock	S	4440	$19.4526	Disposed	35994	Direct
2026-01-13	Common Stock	S	11663	$20.5392	Disposed	24331	Direct
2026-01-13	Common Stock	S	1923	$21.0808	Disposed	22408	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-13	Stock Option (Right to Buy)	$8.39	M	27000	Disposed	2034-04-16	Common Stock (27000)	Direct

Footnotes

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.86 per share, inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.02 per share, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.15 per share, inclusive.

F6: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.